The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
Metrics: PDF 1646 views | HTML 1632 views | ?
Christophe Deben1,2, An Wouters1, Ken Op de Beeck1,4, Jolien van Den Bossche1, Julie Jacobs1, Karen Zwaenepoel2, Marc Peeters1,3, Jan Van Meerbeeck5, Filip Lardon1, Christian Rolfo3,6, Vanessa Deschoolmeester1,2,* and Patrick Pauwels1,2
1 Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
2 Department of Pathology, Antwerp University Hospital, Antwerp, Belgium
3 Department of Medical Oncology, Antwerp University Hospital, Antwerp, Belgium
4 Center for Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
5 Department of Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium
6 Phase-1 Early Clinical Trials Unit, Antwerp University Hospital, Antwerp, Belgium
* These author is a Co-senior author
Christian Rolfo, email:
Keywords: cisplatin, MDM2, p53, NSCLC, synergism
Received: March 30, 2015 Accepted: May 30, 2015 Published: June 10, 2015
The p53/MDM2 interaction has been a well-studied target for new drug design leading to the development of the small molecule inhibitor Nutlin-3. Our objectives were to combine Nutlin-3 with cisplatin (CDDP), a well-known activator of the p53 pathway, in a series of non-small cell lung cancer cell lines in order to increase the cytotoxic response to CDDP. We report that sequential treatment (CDDP followed by Nutlin-3), but not simultaneous treatment, resulted in strong synergism. Combination treatment induced p53’s transcriptional activity, resulting in increased mRNA and protein levels of MDM2, p21, PUMA and BAX. In addition we report the induction of a strong p53 dependent apoptotic response and induction of G2/M cell cycle arrest. The strongest synergistic effect was observed at low doses of both CDDP and Nutlin-3, which could result in fewer (off-target) side effects while maintaining a strong cytotoxic effect. Our results indicate a promising preclinical potential, emphasizing the importance of the applied treatment scheme and the presence of wild type p53 for the combination of CDDP and Nutlin-3.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.